Sportradar To Release Fourth Quarter 2022 Financial Results 15-02-2023, 20:08

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

EBC Financial Group Partners with Shakti Regeneration Institute to Empower Marginalised Communities and Promote Indigenous Conservation Efforts 27-01-2025, 22:54